Yaping Huang

ORCID: 0009-0008-8548-0555
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • BRCA gene mutations in cancer
  • Male Breast Health Studies
  • Tuberculosis Research and Epidemiology
  • Food Science and Nutritional Studies
  • Regional Economic and Spatial Analysis
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Economic and Environmental Valuation
  • Breast Cancer Treatment Studies
  • Land Use and Ecosystem Services
  • Pancreatic and Hepatic Oncology Research
  • Cancer, Hypoxia, and Metabolism
  • RNA modifications and cancer
  • Food composition and properties
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Drug-Induced Adverse Reactions
  • Energy, Environment, Economic Growth
  • Polysaccharides Composition and Applications
  • Economic and Financial Impacts of Cancer
  • Cancer Treatment and Pharmacology
  • Cancer and Skin Lesions
  • COVID-19 and healthcare impacts
  • Ovarian function and disorders
  • Reproductive Biology and Fertility
  • Pneumocystis jirovecii pneumonia detection and treatment

Fujian Medical University
2023-2025

Zhangzhou Municipal Hospital of Fujian Province
2025

Fujian Provincial Hospital
2024

Fuzhou University
2024

First Affiliated Hospital of Fujian Medical University
2023

Zhejiang University
2022

Huazhong University of Science and Technology
2012-2022

Wuhan Engineering Science & Technology Institute
2022

Wuhan University
2022

Ministry of Natural Resources
2022

The use of Totally Implantable Venous Access Port (TIVAP) has gained importance in chemotherapy for cancer patients due to its ability reduce complications compared conventional central venous catheters. Chemotherapy breast often requires long-term access, and the choice device can impact both treatment efficacy patient quality life. This study randomly divided 355 patients, who were treated from January 2022 2023, into TIVAP group (n = 177) control 178) evaluate application effect TIVAP....

10.1007/s12672-025-02020-5 article EN cc-by-nc-nd Discover Oncology 2025-03-24

Abstract Tamoxifen (TAM), a selective estrogen receptor (ER) modulator, has received approval for use in patients with breast cancer (BC) exhibiting positive ER expression. Given the widespread clinical of TAM, comprehensive real‐world study its adverse events (AEs) is warranted. The database analysis, sourced from Food and Drug Administration Adverse Event Reporting System (FAERS), covers period first quarter 2014 to third 2023. A disproportionality analysis was conducted quantify...

10.1002/ijc.35193 article EN International Journal of Cancer 2024-09-21

Background Tafamidis emerged as the first FDA-approved drug for treating termed amyloid fibrils. This study aims to analyze adverse events (AEs) related tafamidis from second quarter (Q2) of 2019 fourth (Q4) 2023 FDA event reporting system (FAERS) database.

10.1080/14740338.2024.2438751 article EN Expert Opinion on Drug Safety 2024-12-05

Abstract STUDY QUESTION Is it economically worthwhile to use GnRH agonist (GnRHa) prevent menopausal symptoms (MS) and protect fertility in premenopausal women with breast cancer (BC) during chemotherapy from the US perspective? SUMMARY ANSWER It is cost-effective administer GnRHa order forefend MS patients BC when willingness-to-pay (WTP) threshold $50 000.00 per quality-adjusted life-year (QALY), preserve young who undergo oocyte cryopreservation (OC), or no OC, WTP thresholds live birth...

10.1093/humrep/dead073 article EN Human Reproduction 2023-04-19

Background: Life expectancy for patients with malignant tumors has been significantly improved since the presence of programmed cell death protein-1/programmed protein ligand-1 (PD-1/PD-L1) inhibitors in 2014, but they impose heavy financial burdens patients, healthcare system and nations. The objective this study was to determine survival benefits, toxicities, monetary quantify their values. Methods: Randomized controlled trials (RCTs) PD-1/PD-L1 were identified clinical benefits quantified...

10.3389/fphar.2023.1114304 article EN cc-by Frontiers in Pharmacology 2023-02-23

Metropolitan areas in China are not only the core spatial carriers of urbanization development but also main generators land use carbon emission (LUCE). However, existing research lacks comparative studies on differential patterns and impact factors LUCE different stages metropolitan areas. Therefore, this paper deeply analyzes characteristics coupling coordination degree (CCD) economy contributive coefficient (ECC) ecological support (ESC) three Yangtze River Economic Belt (YREB), China....

10.3390/land11101835 article EN cc-by Land 2022-10-18

This paper focuses on key issues in the analysis of underdeveloped towns mountainous area. First, it provides an overview and critique methodological approaches to review drawbacks rapid urbanization Eastern China. Second, example Macheng is used demonstrate dilemma faced by poverty-stricken areas. Third, this article explores ways which optimal model can be developed or redeveloped improve economic competitiveness while preserving enhancing natural environment mountains. The five aspects...

10.1109/iacp.2012.6342990 article EN 2012-06-01
Coming Soon ...